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Abstract
Influenza A and B infections are a worldwide health concern to both humans and animals. High genetic evolution rates of
the influenza virus allow the constant emergence of new strains and cause illness variation. Since human influenza
infections are often complicated by secondary factors such as age and underlying medical conditions, strain or subtype
specific clinical features are difficult to assess. Here we infected ferrets with 13 currently circulating influenza strains
(including strains of pandemic 2009 H1N1 [H1N1pdm] and seasonal A/H1N1, A/H3N2, and B viruses). The clinical parameters
were measured daily for 14 days in stable environmental conditions to compare clinical characteristics. We found that
H1N1pdm strains had a more severe physiological impact than all season strains where pandemic A/California/07/2009 was
the most clinically pathogenic pandemic strain. The most serious illness among seasonal A/H1N1 and A/H3N2 groups was
caused by A/Solomon Islands/03/2006 and A/Perth/16/2009, respectively. Among the 13 studied strains, B/Hubei-
Wujiagang/158/2009 presented the mildest clinical symptoms. We have also discovered that disease severity (by clinical
illness and histopathology) correlated with influenza specific antibody response but not viral replication in the upper
respiratory tract. H1N1pdm induced the highest and most rapid antibody response followed by seasonal A/H3N2, seasonal
A/H1N1 and seasonal influenza B (with B/Hubei-Wujiagang/158/2009 inducing the weakest response). Our study is the first
to compare the clinical features of multiple circulating influenza strains in ferrets. These findings will help to characterize the
clinical pictures of specific influenza strains as well as give insights into the development and administration of appropriate
influenza therapeutics.
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Introduction
Influenza is a RNA virus of the orthomyxoviridae family and
causes respiratory infections among birds and mammals [1,2].
Since the first documented influenza pandemic in 1918–20, there
have been six influenza pandemics that have resulted in millions of
deaths worldwide, where the fatality rate can reach up to 2.0% as
in the case of pandemic 1918–20 [2–5]. In addition to pandemic
influenza outbreaks, seasonal influenza epidemics occur in regions
of the globe annually and result in approximately three to five
million cases of severe illness, and 250,000 to 500,000 deaths each
year [6]. Influenza infections are caused by influenza A, B or C
species where most cases are due to A or B viruses [2,4,7].
Specifically, influenza A can be classified into several subtypes
according to the specific combination of its two surface molecules,
haemagglutinin (HA) and neuraminidase (NA). There are 16 HA
isotypes (H1–H16) and 9 NA isotypes (N1–N9) [2,8]. Influenza B
has only one subtype [9].
The high diversity of influenza A is attributed to genetic
mutation and gene reassortment which occurs by genome segment
swapping among various subtypes while infecting the same host at
the same time [3,5,10]. Throughout history, several influenza
pandemics including pandemic 2009 H1N1 (H1N1pdm) resulted
from gene reassortment among several influenza subtype lineages
while seasonal epidemics occurred due to rapid gene mutation
[2,3,5,10,11]. Influenza A/H3N2 and A/H1N1 are the current
circulating seasonal subtypes [7,12]. Interestingly, since early 2009
to 2010, the A/H1N1 subtype was responsible for both seasonal
influenza infections and a pandemic influenza outbreak but the
actual causative strains for each respective A/H1N1 infection were
genetically unrelated [13]. Strain variation derived from either of
the two mechanisms can cause significant differences in infectivity
despite the strains being classified in the same subtype. In contrast,
influenza B has a slower mutation rate [14,15], and due to its
limited host tropism, gene reassortment is rare [16,17]. Conse-
quently, there are much fewer genetic (and antigenic) influenza B
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found as regional epidemics [4,7]. Various influenza subtypes as
well as genetic alterations can cause different epidemics and trigger
immune responses upon infection. However, the association
between human clinical outcomes with the influenza genetic
background is not clear because the infections are often
complicated by secondary factors such as age differences and
underlying medical conditions [18,19].
The most common clinical responses caused by influenza
include a sudden onset of fever, sneezing, dry cough, rhinorrhea,
myalgia and lethargy [2–4]. These symptoms result from the
body’s inflammatory and defence mechanisms during influenza
infection and are often used as indices to compare disease severity
in humans between influenza subtypes [3,5,7,18–21]. After
exposure to the virus, the body generates antibodies against the
specific influenza strain it has encountered. Anti-HA being the
most important humoral immune response creates immunity to
the same or homologous influenza strains [2]. Some antibodies
have neutralizing ability to interfere with viral entry to the host
cell. Haemagglutination inhibition (HI) and microneutralization
(MN) are the two standard assays to measure anti-HA and
influenza neutralizing antibody levels respectively [22].
Since 2009, the predominant influenza strain shifted from
H1N1pdm to the new A/H3N2 and Influenza B strains in several
regions of the globe [23]. To date, little is known about the new
influenza viruses and their clinical and immunopathology
correlation. In this study, we investigated and compared clinical
characteristics caused by the most current influenza strains
including A/H1N1 (H1N1pdm and former seasonal A/H1N1),
seasonal A/H3N2 and seasonal Influenza B in ferrets during a 14-
day time course to determine the clinical picture of each influenza
strain infection. Ferrets are a suitable animal model for influenza
infection because they display similar flu-like symptoms and
immune responses to humans [24–31]. Specifically, daily mea-
surements in body temperature, body weight, nasal discharge,
sneezing, and animal inactivity score upon infection were
analysed. We have also evaluated influenza specific antibody
responses, histopathology and viral replication for various
influenza strains infections. Our findings will help clarify the
influenza clinical pictures of the current circulating strains and the
parallel immunopathology association. The work here will
facilitate the development of future influenza diagnostics and
anti-viral treatments.
Results
Clinical comparison of seasonal A/H1N1 influenza strains
showed A/Solomon Islands/03/2006 to have severe
clinical disease
Before the emergence of H1N1pdm, seasonal A/H1N1 was a
major concern circulating in many regions of the world [7,12,13].
Although, the emergence of H1N1pdm virus seemed to preside
after 2009 [30], the clinical examination of seasonal A/H1N1
infection is important not only to determine the clinical trends of
typical seasonal A/H1N1 infections but also to differentiate the
immunopathological responses between the pandemic and
seasonal A/H1N1 infections.
We investigated two seasonal A/H1N1 influenza viruses, A/
Solomon Islands/03/2006 (Sol/03) and A/Brisbane/59/2007
(Bris/59). Both seasonal A/H1N1 viruses were recommended for
the A/H1N1 component of seasonal influenza vaccines in 2008 and
2009 [32]. Ferrets were infected with either seasonal A/H1N1 virus
at 10
6 50% egg infectious dosage (EID50) and body temperature,
weight, inactivity level, sneezing and nasal discharge from each
group were observed daily until Day 14 post-infection (pI). We have
also examined uninfected ferrets for 14 days as additional healthy
control. Uninfected ferrets did not display fever (temperature never
being 1% above the baseline) and weight loss. Furthermore, no sign
of nasal discharge, sneezing, and inactivity was observed (Figure S1).
In contrast, both seasonal A/H1N1 influenza viruses gave an
immediate spike in body temperature at Day 2 pI with Sol/03
infection displaying a more rapid and higher response (Figure 1A).
In addition, Sol/03 had a smaller second rise in temperature from
Day 3 to 8 pI (Day 5 and 8 pI with pAnova,0.05). Bris/59 recovered
to the pre-infection level after Day 3 although it gave a temperature
decline from Day 9 to 13. In contrast to body temperature, Bris/59
animals lost weight more rapidly than Sol/03 animals (although not
significant). However, Sol/03 animals did not show weight recovery
during the observation period where Bris/59 animals recovered
(Figure 1B, Day 11 to 14 pI, pAnova,0.05). More Sol/03 animals
exhibited nasal discharge and appeared lethargic compared to Bris/
59animals,although nosneezingwasobservedfromSol/03animals
(Panel 1C). In summary, Sol/03 infected animals experienced
prolonged weight loss and fever, higher incidence of nasal discharge
and were more lethargic in comparison to the Bris/59 infected
animals. Sol/03 infection had a more severe effect on ferrets.
A/California/07/2009 infection caused a more severe
clinical disease compared to other H1N1pdm strains
H1N1pdm influenza virus emerged in early 2009 spreading
quickly around the globe where several strains were isolated from
various locations [13]. A/California/07/2009 (Cal/07) and A/
Mexico/4108/2009 (Mex/4108) are two of the earliest isolates
identified and have been shown to be serologically and genetically
related. A/Utah/20/2009 (Utah/20) was grown in tissue culture
and is serologically related to Cal/07 (data not shown). A/South
Carolina/2/2010 (SC/2) was collected in 2010 and it belongs to
H1N1pdm lineage which is also serologically related to Cal/07
(data not shown). Here we sought to compare the physiological
impact of Cal/07, Mex/4108, Utah/20, and SC/2 infections in
ferrets by observing the clinical features following infection.
Ferrets were infected as above except with Mex/4108 or SC/2 at
10
5 EID50, Cal/07 at 10
4 EID50 or Utah/20 at 10
4.3 50% tissue
culture infectious dosage (TCID50). Furthermore, to show infection
at the same dose, we included a clinical data comparison between
H1N1pdm infections (Figure S2) at 10
6 EID50. Clinical signs were
observed daily for 14 days pI. Among the H1N1pdm strains from
2009, although ferrets infected by Cal/07 showed one-day-delayed
temperaturerise,Cal/07induced the longestduration offeverwhile
Mex/4018 and Utah/20 induced a biphasic pattern of fever
(Figure 2A). Cal/07 infected animals also experienced the most
severe weight loss among all four strains. SC/2 infection induced a
substantial level of fever in the animals at Day 2 and the
temperature gradually reached near the basal level at Day 8 pI.
Ferrets infected with Mex/4108 recovered the earliest where their
body temperatures returned to the pre-infection level and body
weights started to recover after Day 7 pI (Figure 2A and 2B).
Conversely, the weight of Cal/07 and Utah/20 ferrets did not
recover during the observation period and there was a profound
body temperature decline after Day 7 pI. The average weights from
the SC/2 infected animals showed recovery but did not reach the
pre-infection level at Day 14 pI. SC/2 infected animals had the
highest incidence of nasal discharge followed by Cal/07 infected
cohorts which appeared the most lethargic (highest inactivity index)
(Panel 2C). Mex/4108 infected animals had the highest observed
incidence of sneezing followed by Cal/07 infected animals. No
sneezing was observed from Utah/20 infected ferrets. Taken
together these results showed Cal/07 had the most severe
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homology among the four pandemic strains.
A/Perth/16/2009 infection gave more severe clinical
symptoms compared to other A/H3N2 seasonal influenza
strains
A/H3N2 virus is also a common seasonal influenza A subtype
in current circulation [32]. Four strains of A/H3N2 were
examined in this study: A/Brisbane/10/2007 (Bris/10), A/
Wisconsin/15/2009 (Wis/15), A/Perth/16/2009 (Perth/16), and
A/Victoria/210/2009 (Vic/210). These strains have been recom-
mended for previous and current year influenza vaccine
preparations demonstrating that they are serologically important
and have geographical prevalence [32].
Ferrets were infected as above except with A/H3N2 influenza
strains at 10
6 EID50. Daily clinical data were collected until Day
14 pI. Perth/16, Vic/210, and Bris/10 infection resulted in an
Figure 1. A/Solomon Islands/03/2006 seasonal A/H1N1 subtype showed more severe clinical disease compared to A/Brisbane/59/
2007. Clinical signs of A/Brisbane/59/2007 (N=14, 10
6 EID50) or A/Solomon Islands/03/2006 (N=8, 10
6 EID50) infected ferrets were measured daily
over 14 days. Temperature A) and weight B) were recorded daily until end day and are expressed as percentage relative to the pre-infection level at
Day 0. Percent nasal discharge, percent sneezing and inactivity index C) were observed daily and the highest percentages and fractions of infected
ferrets displaying symptoms are shown. Physical inactivity index measures the degree to which ferrets respond to environmental stimuli with a basal
level of 1.000. Error bars represent standard error of the mean. *p,0.05 from Student’s t-test.
doi:10.1371/journal.pone.0027512.g001
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Perth/16 fever was similar to the seasonal A/H1N1 fevers
(Figure 3A and 1A). Conversely, the temperature elevation
induced by Wis/15 was delayed one day following a decline on
Day 2 pI. Although Wis/15 fever (Day 3 pI) was the mildest
among the four infections, the increase in body temperature was
similar to Perth/16 infection (Figure 3A). For all the A/H3N2
infections, animal body temperature recovered to the pre-
infection level one day following the initial fever, except for
Wis/15 infected animals which experienced a long duration of
hypothermia from Day 5 to Day 14 pI. Perth/16 and Vic/210
infections led to substantial weight loss where animal weights did
not recover throughout the observed time course (Figure 3B).
Wis/15 infected animals lost weight gradually until Day 7 and
then slowly recovered. In contrast to the other A/H3N2 viruses,
Bris/10 infection began with a weight-gaining spike at Day 2 pI
and weight loss did not occur until Day 13. This response was not
common among all the influenza viruses investigated. In regard
Figure 2. A/California/07/2009 infection gave the most severe clinical symptoms of H1N1pdm virus strains. Clinical signs of ferrets
infected with A/Mexico/4108/2009 (N=18, 10
5 EID50), A/California/07/2009 (N=8, 10
4 EID50), A/South Carolina/2/2010 (N=12, 10
5 EID50), or A/Utah/
20/2009 (N=10, 10
4.3 TCID50) were measured over a 14-day time course. Body temperature A) and weight B) were recorded daily until Day 14 pI. Both
measurements are expressed as percentage relative to the pre-infection level at Day 0. C) summarises percent nasal discharge, percent sneezing and
inactivity index. These signs were observed daily and the highest percentages and fractions of infected ferrets displaying symptoms are shown.
Physical inactivity index measures the degree to which ferrets respond to environmental stimuli with a basal level of 1.000. Error bars represent
standard error of the mean. *pAnova,0.05 and usignificant difference from A/California/07/2009 by Bonferroni-holm test (post-hoc analysis).
doi:10.1371/journal.pone.0027512.g002
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was the mildest among the four A/H3N2 strains, although it
rendered the highest incidence of nasal discharge. Furthermore,
Bris/10 animals appeared to be the most lethargic followed by
the Vic/210, Perth/16 and Wis/15 infected animals. Perth/16
infection caused the most incidence of sneezing which was not
observed in Wis/15 infection (Panel 3C). Taken together the
results showed that Bris/10 and Wis/15 infection were milder but
instigated different physiological conditions. Moreover, Perth/16
infection was the most severe infection based on our studied
clinical traits.
Clinical characteristics of B/Florida/04/2006 and B/Hubei-
Wujiagang/158/2009 are similar but distinct from B/
Brisbane/60/2008 infection
Influenza B viruses belong to a species of influenza that is
antigenically and genetically distant from influenza A viruses. B
Figure 3. A/Perth/16/2009 infection was more severe than other A/H3N2 seasonal influenza strains. Ferrets were infected with A/
Brisbane/10/2007 (N=6), A/Wisconsin/15/2009 (N=6), A/Perth/16/2009 (N=12), or A/Victoria/210/2009 (N=10 and N=7 after Day 8 pI) and clinical
signs were measured daily over a 14-day time course. The same dosage (10
6 EID50) was used for all three infections. Body temperature A) and body
weight B) were recorded daily to Day 14 pI. Both measurements are expressed as percentage relative to the pre-infection level at Day 0. Panel C
summarises percent nasal discharge, percent sneezing and inactivity index. Percent nasal discharge and percent sneezing were observed daily and
the highest percentages and fractions of infected ferrets displaying symptoms are shown. Physical inactivity index measures the degree to which
ferrets respond to environmental stimuli with a basal level of 1.000. Error bars represent standard error of the mean. *pAnova,0.05 and usignificant
difference from A/Perth/16/2009 by Bonferroni-holm test (post-hoc analysis).
doi:10.1371/journal.pone.0027512.g003
Distinct Clinical Features of Influenza Infections
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27512infections are not as common as influenza A virus infections and
the host range is limited, with humans being the primary hosts [9].
Ferrets infected by influenza B also displayed similar flu-like
symptoms and immune responses to humans, therefore they are a
suitable model to study influenza B immunopathology [26]. We
examined clinical characteristics of three strains of B viruses: B/
Brisbane/60/2008 (B/Bris), B/Florida/04/2006 (B/Fla), and B/
Hubei-Wujiagang/158/2009 (B/Hubei) which have been recom-
mended for previous and/or current influenza vaccine inclusion
[32].
Ferrets were infected similarly as above except with influenza B
strains at 10
6 EID50 and daily clinical data was observed until Day
14 pI. All three infections induced fever on Day 2 pI (Figure 4A).
On Day 1, B/Bris initiated a temperature decline before a rise. In
opposition, B/Fla and B/Hubei gradually elevated body temper-
ature until Day 2. B/Bris fever was the mildest and most transient
although it gave the highest temperature increase from Day 1 to
Day 2 pI. Following Day 3 pI, body temperature from B/Bris
infected animals dropped below pre-infection level and did not
recover (Figure 4A). Both B/Fla and B/Hubei fever ended on Day
4 pI and then oscillated above and below pre-infection level until
Day 14 pI. In contrast to body temperature trends, B/Bris animals
lost their weights rapidly starting from Day 1 pI. Conversely, B/
Fla and B/Hubei animals did not experience weight loss until Day
2 pI (Figure 4B). B/Bris induced the most weight loss; furthermore
there was a second weight drop from Day 8 to Day 11 pI following
the first recovery and weights did not recover to the basal level on
Day 14 pI. Weight loss in B/Fla and B/Hubei animals was less
severe. B/Fla animals reached peak weight loss Day 2 pI and
recovered to the pre-infection levels after Day 4. B/Hubei animals
had highest weight loss at Day 3 and gradually recovered after
Day 7 (Figure 4B). For both B/Fla and B/Hubei, body weight
fluctuated around pre-infection level after weight recovery. Among
three influenza B viruses, only B/Fla affected ferret activity
response (Panel 4C). B/Fla induced the highest and B/Hubei
induced the lowest nasal discharge incidence. However, the lowest
incidence of sneezing was observed in B/Fla infection although the
difference was not significant. In summary, although the three
influenza B strains provoked different illness conditions, we found
the clinical pattern of B/Bris infection (more weight loss, slower
weight recovery and lower fever) to be different than that of B/Fla
and B/Hubei. B/Fla was similar to B/Hubei infection where B/
Bris seemed to evoke a divergent illness.
Clinical characteristics of various influenza subtype
infections
After the clinical results were compared among each strain of
the same influenza subtype, we grouped the data accordingly:
H1N1pdm, seasonal A/H1N1, seasonal A/H3N2, and seasonal
Influenza B viruses. The grouped data was then compared against
the other subtypes to identify the trends among the subtypes.
In general, influenza induced fever in ferrets at Day 2 pI
(Figure 5A). Seasonal A/H1N1 provoked the highest fever spike
(although not significant) where H1N1pdm induced the longest
fever duration (Day 1 to Day 6 pI with most days pAnova,0.05).
The fever pattern of seasonal A/H3N2 and B infections were
similar; both were mild and recovered after Day 3. Fever in all
season infections was transient and body temperature fluctuated
above and below pre-infection levels following the initial recovery.
Conversely, H1N1pdm animals experienced hypothermia from
Day 7 to Day 10 and gradually recovered by Day 14 (Figure 5A).
The majority of infected animals experienced weight loss Day 1
pI (Figure 5B). Weight loss in influenza B infection was the modest
and peaked on Day 2 then slowly recovered. Seasonal A/H3N2
infected animals gradually lost weight and did not display weight
recovery over the observation period. Seasonal A/H1N1 animals
suffered an early and substantial weight loss that continued from
Day 1 to Day 4. Although their body weights did not reach the
pre-infection level by Day 14 pI, they gradually recuperated
throughout the period. H1N1pdm animals underwent an
extensive weight loss during the entire period. Their weights
decreased consistently until Day 8 pI (Figure 5B) and the weight
recovery was the lowest among all the studied influenza species
(pAnova,0.05).
H1N1pdm animals appeared the most lethargic while the
inactivity levels between the three seasonal influenza infected
animals were similar (Panel 5C). Among the seasonal infections,
A/H3N2 viruses induced the highest incidence of sneezing. Even
though nasal discharge was observed in all influenza infections,
influenza B infection gave the highest percentage of animals
showing nasal discharge. Taking into account all the investigated
clinical parameters, H1N1pdm had the most profound physiolog-
ical impact on ferrets due to the longest weight loss period,
minimal weight recovery, longest duration of fever, the highest
lethargy and prominent sneezing and nasal discharge. Seasonal
viruses induced differential degrees of clinical features while
influenza B viruses caused the mildest illness. In addition, further
analysis was performed between subtype infections (Figure S3) all
at 10
6EID50.
Viral replication of representative influenza strains in the
upper respiratory tract of infected ferrets
We next sought to determine if disease severity was associated
with viral replication, specifically the viral titer in the upper
respiratory tract of infected ferrets. One strain was chosen as the
representative virus for each subtype. Nasal washes were collected
on Day 3 or 4 and Day 7 pI and titrated on Madin-Darby Canine
Kidney (MDCK) cells to measure viral titer. All the representative
strains were detected in either Day 3 or Day 4 but were cleared by
Day 7 pI (Figure 6). In addition, Influenza B virus titer was found
at the similar level to H1N1pdm at Day 3 pI and significantly
higher (pAnova,0.005) than seasonal A/H1N1.
Differential antibody responses induced by various
influenza strains
The correlation between the antibody responses with intranasal
viral titre and infection severity is unclear. We found that Day 7
pI, HI titers against corresponding H1N1pdm was significantly
higher (p,0.05) than HI titers against the other corresponding
seasonal influenza subtypes (Figure 7A and Table 1). The titer
level from pandemic infection was elevated more rapidly than the
seasonal subtypes. The similar trend was also found in MN assays
where high level of neutralizing antibody titers stimulated by
H1N1pdm infection was the most rapidly raised on Day 7 pI
(Figure 7A and Table 1). We could not detect neutralizing
antibodies for seasonal A/H1N1 and influenza B on Day 7.
Antibody response induced by B/Hubei infection was significantly
lower than those of other infections (Figure 7A & 7B). We found
that the weak response from B/Hubei was not accompanied by an
impaired antibody isotype class switching event (Figure 7A). There
was no significant difference in the class switching process induced
by various influenza subtypes. Anti-influenza ferret IgM was the
primary antibody species on Day 7 and gradually replaced by anti-
influenza IgG on Day 14 pI (Figure 7A). However, IgM species
induced by influenza A infection had a longer half life in the blood
stream than influenza B induced IgM. We also found HI levels
were equivalent among each subtype of influenza A species but HI
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species (Figure 7B). In summary, influenza specific antibody
response induced by H1N1pdm infection has the highest
magnitude and was the most rapid, followed by seasonal A/
H3N2, seasonal A/H1N1, and seasonal influenza B (Figure 7A
and 7B).
Figure 4. Comparison of clinical features among influenza B subtypes showed B/Brisbane/60/2008 infection to give divergent
illness. Clinical signs of ferrets infected with B/Brisbane/60/2008 (N=6), B/Florida/04/2006 (N=8), or B/Hubei-Wujiagang/158/2009 (N=6) were
measured daily in a 14-day time course. The same dosage (10
6 EID50) was used for all three infections. Body temperature A) and body weight B) were
recorded daily for 14 days. Both measurements are expressed as percentage relative to the pre-infection level at Day 0. C) summarises qualitative
clinical signs: percent nasal discharge and percent sneezing were observed daily and the highest percentages and fractions of infected ferrets
displaying symptoms are shown. Physical inactivity index measures the degree to which ferrets respond to environmental stimuli with a basal level of
1.000. Error bars represent standard error of the mean. *pAnova,0.05 and usignificant difference from B/Brisbane/60/2008 by Bonferroni-holm test
(post-hoc analysis).
doi:10.1371/journal.pone.0027512.g004
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In order to strengthen the clinical observations, we preformed a
time course lung histopathology study during influenza infection.
Ferrets were infected with representative strains from each
influenza subtype or mock infected as negative control. In the
mock control group, both bronchiolar and alveolar spaces were
clear and no lesions were observed in the lungs on either Day 3 or
7 pI. However, leukocyte plugs were found in several bronchiolar
lumens with necrotizing bronchiolar walls and sloughing of
epithelial cells in the seasonal H1N1 (Day 2 pI) and influenza B
(Day 3 pI) infected lungs (occasionally in the alveolar space),
indicated by the white arrows (Figure 8). The majority of leukocyte
plugs were cleared from the lumens with minimal epithelial
shedding on Day 7 pI for both infections. In H3N2 infected lungs,
no leukocyte plugs or lesions were found in the air space on Day 3
pI, similar to the mock control. However, alveolar consolidation
and pulmonary haemorrhages progressively appeared in a number
of areas in the H3N2 infected lobes on Day 7 pI evidenced by
Figure 5. Influenza A/H1N1, A/H3N2, and B infections in ferrets gives distinct clinical trends. Ferret clinical data from H1N1pdm (N=48),
seasonal A/H1N1 (N=22), seasonal A/H3N2 (N=34 and N=31 after Day 8 pI), and seasonal influenza B (N=20) infections were combined respectively
for inter-group comparison. The combined body temperature A) and body weight B) are expressed as percentage relative to the pre-infection level at
Day 0. Percent nasal discharge, percent sneezing, and physical inactivity index are recalculated for each group and summarized in C). Amount of
animals displaying nasal discharge and sneezing from each group were combined and calculated as percentage for each day. Only the highest
percentages and fractions from each group are shown. Physical inactivity index is the pooled measure of which infected ferrets by each group
respond to environmental stimuli with a basal level of 1.000. Error bars stand for standard error of the mean. *pAnova,0.05 and usignificant difference
from H1N1pdm by Bonferroni-holm test (post-hoc analysis).
doi:10.1371/journal.pone.0027512.g005
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neutrophils) and interstitial edema in the bronchiolar and alveolar
spaces, indicated by the white arrows. Hyperplasia of the alveolar
epithelium was also observed (the enclosed area of the white circle)
on Day 7 pI. H1N1pdm Infected lungs showed acute and severe
inflammation on Day 3 pI evidenced by necrotizing bronchiolitis
(sloughing of epithelial lining and leukocyte plugs) and alveolar
consolidations and haemorrhage (massive number of leukocytes
and edema fluid in the alveolar space), indicated by the white
arrows. Hyperplasia of alveolar type II pneumocytes was observed
(the enclosed area of the white circle) on Day 3 pI. The pathology
minimized by Day 7 pI where more leukocyte plugs and
haemorrhages were present in the lungs. Moreover, profound
desquamation of bronchiolar and alveolar epithelial cells caused
partial or almost complete disappearance of air space wall lining.
Discussion
This study demonstrated a broad spectrum comparison of
clinical characteristics among several prevalent influenza strains
that have circulated in recent years. Often the compilation of
human clinical data is complicated by secondary factors such as
age differences, underlying medical conditions, unknown exposing
dosage and influenza strain identity in different seasons [18,19].
Here we minimized the secondary factors by using the ferret
experimental model to ensure the clinical impact of each strain
was due to its own pathogenicity. From our findings, H1N1pdm
infection displayed the most severe clinical outcome and required
a longer recovery period. Seasonal influenza subtypes caused
distinct illnesses although strain-to-strain variation existed among
each subtype. Our study offers an in-depth clinical discussion of
circulating influenza strains that will aid future influenza
diagnostics as well as facilitate the design of potential anti-
influenza treatments.
Similar to high pathogenic avian influenza H5N1, H1N1pdm
can cause acute respiratory distress syndromes where severe
inflammation is developed in the lung and leads to respiratory
failure and death [25,31,33,34]. From human clinical observa-
tions, the majority of H1N1pdm hospitalized patients had at least
one previous medical condition [20,35]. Therefore, it is unclear if
the pandemic strains themselves are more virulent than the
seasonal strains or the virus is synergistic with predisposed
conditions. We found that H1N1pdm provoked a long duration
of elevated body temperature. Interestingly, this finding was not
only concurrent with a previously reported study of a different
H1N1pdm strain (A/Quebec/147365/2009) [24] but was in
parallel with high pathogenic avian H5N1 infection in ferrets [31].
In addition, this observation was in agreement with our previous
finding where a prolonged fever was induced with Cal/07
infection [29]. The H1N1pdm infections were capable of inducing
profound fever and the long duration was possibly due to sustained
levels of proinflammatory cytokines that are released during
infection as previously seen [25,29]. In contrast, seasonal A/H1N1
infections induced a higher magnitude but very transient fever
compared to H1N1pdm. This observation is supported by our
previous study that the magnitude of Bris/59 fever was higher
than Cal/07 fever at the same high dosage (10
6 EID50) [29].
Weight loss was more prominent in H1N1pdm infection and
animals required a longer recovery period which may have been
due to tissue damage that was caused by profound cytokine
production and broader tissue tropism of pandemic strains [25,27–
29]. These results were also supported by human clinical
observations where previously healthy individuals developed
severe illness by the intense inflammation in the respiratory
Figure 6. Influenza viral replication in the upper respiratory tract of ferrets following intranasal infection. One most recent circulating
representative strain for each subtype was chosen as follows: Mex/4108 for H1N1pdm, Bris/59 for seasonal A/H1N1, Vic/210 for seasonal A/H3N2, and
B/Hubei for seasonal influenza B. All nasal wash samples from infected ferrets were collected on Day 3 and Day 7 pI except for Vic/210 infection (Day
4 and Day 7 pI) and titrated on MDCK cells (TCID50/mL). Statistical analysis was only conducted on samples collected on the same day pI.
*pAnova,0.005 and significant difference was found between H1N1pdm with seasonal H1N1 by Bonferroni-holm test (post-hoc analysis).
doi:10.1371/journal.pone.0027512.g006
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sustained fever might have affected the animals’ appetite as
weight recovery did not occur until temperature returned to
baseline. The difference in the clinical characteristics between
seasonal and H1N1pdm infection could be explained by their
distant genetic background [13]. Although, H1N1pdm caused
severe illness, these strains were cleared by Day 7 pI like other
seasonal viruses. B species infected animals did not show high fever
and prominent weight loss, however they induced the highest
incidence of nasal discharge (B/Fla and B/Bris specifically) among
the 13 studied influenza strains. In addition, high viral titer found
in the nasal washes of influenza B virus infected ferrets on Day 3 pI
implied that influenza B replicated as efficiently as H1N1pdm in
the upper respiratory tract. These observations suggested that
influenza B viruses were capable of establishing an infection but
failed to give ferrets severe illness. Since all strains replicated at a
similar efficiency in MDCK cells (data not shown), the resulting
higher titer was due to increased viral replication specifically in
ferrets. The similar clinical effects of B/Fla and B/Hubei could
possibly be due to close genetic background as they both belong to
the B/Yamagata/16/88 lineage whereas B/Bris is closely related
to B/Victoria/2/87 lineage [36]. The differential clinical
outcomes from different A/H3N2 strain infections can also be
related to the divergence in their genetic background [37]. These
findings could add insight into the recent A/H3N2 outbreak in
North America by suggesting that not only is the current seasonal
A/H3N2 strains more pathogenic than the previous circulating A/
H3N2 strains (e.g. Bris/10) but also previous A/H3N2 vaccination
provides minimal protection against the new A/H3N2 strains.
Our results support the concept that differences in genetic
background among the various influenza subtypes or strains can
cause distinct clinical characteristics.
Antibody response plays a central role in immunity. The
specificity and quantity of antibody determine the strength of
humoral defence when a secondary exposure to the same or
related pathogen occurs. In this study, we found that the antibody
responses correlated with the severity of influenza infections. The
antibody titre from H1N1pdm infection was the highest and was
induced most rapidly followed by seasonal A/H3N2, seasonal A/
H1N1 and then Influenza B. This observation was concurrent
with infection severity (in both clinical characteristics and
histopathology). H1N1pdm induced the most severe illness
(maximal weight lost, slowest weight recovery, longest fever
duration and the most prominent influenza-induced pulmonary
lesions and inflammation) followed by seasonal A/H3N2 (gradual
weight loss throughout the time course but did not recover on Day
14 pI with deteriorating pulmonary histopathology), seasonal A/
H1N1 (acute onset of weight loss with early occurrence of
bronchiolitis but gradual recovery throughout the observation
period) and then Influenza B infection (mild weight loss and early
recovery with mild bronchiolitis). In addition, B/Hubei infection
induced the least severe clinical illness and also the lowest antibody
titer. Similar findings were also observed in our previous study
where HI titer was higher in Cal/07 than in Bris/59 animals [29].
Similarly, it was shown that the attenuated mutants of a
H1N1pdm strain, A/New York/1682/2009, induced lower
neutralizing antibody levels than the wild type but induced
Figure 7. Influenza induced antibody responses mirror specific influenza strain illness. A) Time course of influenza induced antibody
responses for various subtypes. Ferret anti-sera taken at the indicated days pI were used to measure HI, neutralizing antibodies and relative IgG or
IgM levels. Student’s t-test was conducted to compare with results on Day 0, *p,0.05. B) Day 14 pI HI titers from individual animals infected by
corresponding influenza strains. HIs of A/Mexico/4108/2009 infected animal sera was used to compare with HIs of other strains using Student’s t-test.
*p,0.005, **p,0.000005.
doi:10.1371/journal.pone.0027512.g007
Table 1. HI and neutralizing antibody titer kinetics post-
influenza infections.
Average HI Titer
{ Average Neut. Ab Titer
{
Day pI Day 0 Day 7 Day 14 Day 0 Day 7 Day 14
H1N1pdm ,3.3 11.1 13.1 ,6.6 12.9 13.4
Seasonal H1N1 ,3.3 5.2* 11* ,6.6 ,6.6* 10.1*
Seasonal H3N2 ,3.3 6* 12.2* ,6.6 8.9* 14.3
Influenza B ,3.3 4.3* 7.9* ,6.6 ,6.6* 9*
{Titer unit in Log2.
*Comparison of HI and neutralizing antibody titers of seasonal viruses to
H1N1pdm on the indicated days pI using Student’s t-test, p,0.05.
doi:10.1371/journal.pone.0027512.t001
Figure 8. Histopathology of influenza subtype infected lung
tissues by H&E stain. The representative strain for each subtype was
selected as follows: Mex/4108 for H1N1pdm, Bris/59 for seasonal H1N1,
Per/16 for seasonal H3N2, and B/Wis (same influenza B lineage as B/
Hubei) for seasonal influenza B. All tissue samples from infected ferrets
were collected on Day 3 and Day 7 pI except for Bris/59 infection (Day 2
and Day 7 pI due to facility scheduling). Representative slides are shown
with 106magnification.
doi:10.1371/journal.pone.0027512.g008
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were similar [30]. Our results reinforced the phenomenon that
illness severity is proportional to antibody response.
Since infections at varying doses are unsuitable for statistical
comparison, we have included a clinical data comparison between
H1N1pdm infections (Figure S2) and between subtype infections
(Figure S3) all at 10
6EID50. Both infections at 10
6EID50 and
infections at lower doses show a similar clinical trend as seen in
both figures. A future study of histology should be conducted to
observe the influenza replication and inflammation sites in tissues
and the corresponding viral titer measurements of the upper and
lower respiratory tract. These findings would demonstrate the
molecular signatures of influenza infections from specific subtypes
that can be paralleled with the clinical findings in this study. The
influence of various risk factors such as pregnancy, obesity and age
to a variety of influenza strain infections should also be assessed. In
addition, this clinical data can be referred to when considering
appropriate treatments and therapies for specific influenza strain
infection and therefore the evaluation of anti-viral efficacy.
Furthermore, when determining the influenza strain virulence
and its impact on the clinical outcome, the genetic background of
the host is also important. For example, Mex/4108 infection was
mild in Balb/c mice but severe in C57BL/6 mice [27,38]. Our
outbred ferret model resembles the genetic diversity in humans.
While the genetic background of the host differs, we were able to
characterize clinical trends when the same virus was infected in
multiple ferrets. Furthermore, the clinical symptoms of a certain
virus were statistically significant when compared to other
infections of different subtypes. Since outbred ferrets showed
similar trends when infected with the same strains which
significantly differed from infection with alternative strains, this
clinical information can be used as an infection baseline model for
human disease, as it is assumed that outbred ferrets have a similar
genetic diversity as humans. This study has led the way to study
influenza infection in a broad spectrum without the confounding
secondary factors and the observations provide discussion for the
understanding of influenza strain specific clinical features and
insights for the design of future anti-influenza treatments.
Materials and Methods
Ethics statement
All work with animals was conducted in strict accordance with
the Canadian Council of Animal Care (CCAC) guidelines. The
University Health Network (UHN) has certification with the
Animals for Research Act (Permit Number: #0045 and #0085 of
the Ontario Ministry of Agriculture, Food and Rural Affairs) and
follows NIH guidelines (OLAW #A5408-01). The animal use
protocol was approved by the Animal Care Committee (ACC) of
the UHN. All infections and sample collections were performed
under 5% isoflurane anaesthesia and all efforts were made to
minimize suffering.
Viruses
All viruses are provided by Center for Disease Control and
Prevention ([CDC], Atlanta, GA, USA) or American Type
Culture Collection ([ATCC], Manassas, VA, USA); four strains
of H1N1pdm (A/California/07/2009, A/Mexico/4108/2009, A/
Utah/20/2009, and A/South Carolina/2/2010), two strains of
seasonal A/H1N1 (A/Brisbane/59/2007 and A/Solomon Is-
lands/03/2006), four strains of seasonal A/H3N2 (A/Brisbane/
10/2007, A/Wisconsin/15/2009, A/Perth/16/2009, and A/
Victoria/210/2009), and three strains of seasonal influenza B
(B/Brisbane/60/2008, B/Florida/04/2006, and B/Hubei-Wujia-
gang/158/2009). Utah/20 was unable to propagate in embryonic
chicken eggs. For the time course kinetics of viral titer in nasal
wash and antibody titer determination, one representative strain
from each subtype was selected: Mex/4108 for H1N1pdm, Bris/
59 for seasonal A/H1N1, Vic/210 for seasonal A/H3N2, and B/
Hubei for seasonal influenza B. For the histopathology time course
study, the following was selected: Mex/4108 for H1N1pdm, Bris/
59 for seasonal A/H1N1, Per/16 for seasonal A/H3N2, and B/
Wisconsin/01/2010 (B/Wis) for seasonal influenza B. These
strains are the most recent circulating strains and all infections are
shown at 10
6EID50. B/Wis was also provided by CDC (Atlanta,
GA, USA) and belongs to the same influenza B lineage as B/
Hubei. All virus work was performed in BSL-2 facility.
Infection and ferrets monitoring
Maintenance and monitoring of ferrets upon infection as
previously described [29]. Briefly, male ferrets 4–6 months old
were purchased from Triple F Farms (Sayre, PA, USA) or bred in
an on-site SPF ferret colony (University Health Network, Toronto,
ON, Canada). Ferrets were shown to be seronegative by HI assay
against circulating influenza A and B strains using the 2009–2010
and 2010–2011 WHO Influenza Reagent Kit for Identification of
Influenza Isolates (WHO collaborating center for surveillance,
epidemiology and control for influenza infection division) before
infection. The kits contain the circulating influenza strains for the
particular year, including: Cal/07 for H1N1pdm, Bris/59 for
seasonal H1N1, Bris/10 for seasonal H3N2 (2009–2010), Per/16
for seasonal H3N2 (2010–2011), B/Bris for B/Victoria lineage,
and B/Fla for B/Yamagata lineage. All viruses in this study were
either the same strains or closely related to those in the WHO kits.
ELISA was also performed on the pre-infection sera and found no
reaction to the viruses in this study. Prior to infection, ferrets were
randomly selected and pair-housed individually in cages contained
in bioclean portable laminar-flow clean-room enclosures (Lab
Products, Seaford, DE) in the BSL-2 animal holding area. Baseline
body temperature and weight were measured on Day 0 for each
animal. Temperatures were measured by using a subcutaneous
implantable temperature transponder (BioMedic Data Systems,
Inc., Seaford, DE). Upon infection, ferrets were anesthetized and
infected with seasonal viruses (10
6 EID50) or pandemic viruses (10
5
EID50 for Mex/4108 and SC/2, 10
4 EID50 for Cal/07 and 10
4.3
TCID50 for Utah/20). The volume of inoculum was 1 mL for
each ferret (0.5 mL in each nostril). Clinical signs (body
temperature, body weight, level of activity, nasal discharge, and
sneezing) were observed daily for 14 days pI. We examined
animals at the same time each day for consistency. Nasal discharge
includes crusty nose, mucous, and transparent exudates/fluids.
The scores were calculated from the total animals displaying any
nasal discharge symptom over the total number of animals. The
sneezing scores were calculated from the total animals found
sneezing over the total number of animals. Scores were calculated
daily for 14 days and only the peak values for each infection are
summarized in panel C in Figures 1,2,3,4,5. The inactivity scoring
system is based on the reference Reuman et al., 1989 [39] to assess
the inactivity level: 0, alert and playful; 0.5, alert but playful only
when stimulated; 1, alert but not playful when stimulated; 2,
neither alert nor playful when stimulated. A relative inacti-
vity index was calculated as follows: S(day 1 to day 14)[score+1]n/
S(day 1 to day 14)n, where n equals the total number of observations.
A value of 1 was added to each observation unit score so that a
score of 0 could be divided by a denominator, resulting in an index
value of 1.0 as the minimum value. Nasal washes from the infected
ferrets were collected on Day 3 or 4 and Day 7 pI in nasal wash
buffer (1%BSA and 100 U/mL penicillin, 100 mg/mL streptomy-
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from infected ferrets Day 0, 7, and 14 pI for the representative
viruses. Penicillin and streptomycin were obtained from Invitrogen
Canada (Burlington, ON, Canada) and BSA was from Wisent Inc.
(Saint-Bruno, QC, Canada).
Determination of viral load
Viral replication in the upper respiratory tract was assessed by
endpoint titration of nasal washes from the infected ferrets in
MDCK cells (TCID50) using haemagglutination as the readout for
positive wells as previously described [29]. Briefly, nasal washes
were initially diluted 10 times in vDMEM (Dulbecco’s modified
Eagle’s medium containing 1% BSA, 25 mM glucose, 1 mM
sodium pyruvate, 4 mM glutamine, 100 U/mL penicillin, 100 mg/
mL streptomycin, 50 mg/mL gentamycin and 1 mg/mL TPCK-
Trypsin) followed by the half log serial dilution from 10
21.0 to
10
26.5 in quadruplicate with vDMEM on MDCKcells in 96-well
flat-bottom plates (SARSTEDT, Inc., Saint-Leonard, QC, Cana-
da). Beforeinfection,MDCK cells were maintainedin the log-phase
with low-passage numbers and grew in cDMEM (DMEM
containing 10% fetal bovine serum, 25 mM glucose, 1 mM sodium
pyruvate, 6 mM glutamine, 1 mM non-essential amino acids,
100 U/mL penicillin, and 100 mg/mL streptomycin). The day
before nasal wash incubation, 2610
4 MDCK cells were seeded into
each well to reach 95% confluence the next day. After 2 hours
incubation of nasal washes samples at 37uC, 5% CO2, samples were
removed and replaced with fresh vDMEM and incubated for 6 days
at 37uC, 5% CO2. On Day 6 pI, supernatants were examined for
presence of virus by influenza haemagglutination of 0.5% turkey
erythrocytes (LampireH Biological Laboratories, Pipersville, PA,
USA). The viral titers were determined as the reciprocal of the
dilution resulting in 50% HA positivity. Viral titers are given as
TCID50/ml fornasalwashes.Allcellculture reagentswereobtained
from Invitrogen Canada except for TPCK-Trypsin (Sigma-Aldrich
Canada Ltd., Oakville, ON, Canada).
Determination of influenza specific antibody responses
Influenza specific antibody responses from the uninfected or
infected ferrets were measured by HI or MN as previously
described [40]. Briefly, receptor destroying enzyme ([RDE],
Accurate Chemical & Scientific Corp., Westbury, NY, USA)
treated ferret anti-sera was serially diluted and HI titers were
determined by the highest dilution that completely inhibited
influenza haemagglutination (4HAU) of turkey erythrocytes. MN
results were evaluated by enzyme-linked immunosorbent assay
(ELISA). Neutralizing antibody titers were determined by the
highest dilution of RDE-treated anti-sera that disrupted infection
(100 TCID50) to MDCK cells at the reading lower than 50%
signal reading measured from virus+cell and cell only controls.
Determination of influenza specific ferret IgG/IgM
isotype relative levels
The determination was based on ELISA technique as previously
described [40]. Briefly, live influenza virions were coated to ELISA
plates (Thermo Fisher Scientific, Rochester, NY, USA) followed
by appropriate blocking and incubation of ferret anti-sera (1:1000).
After the incubation of HRP-anti-ferret IgG or IgM (1 mg/mL,
Rockland Immunochemicals Inc. Gilbertsville, PA, USA), the
plates were developed and read at 490 nm.
Histopathology
Infected ferrets (10
6 EID50, N=3 per group) were sacrificed on
Day 3 and 7 pI (except for Bris/59 which was sacrificed on Day 2
and 7 pI due to facility scheduling) for histopathology. PBS
(diluent for all virus inocula) was used for mock infection control.
Lung tissues excised from the upper and lower left lobes were
formalin-fixed and paraffin embedded. Tissue slides were stained
with hematoxylin/eosin for microscopic assessment.
Statistics
One-way analysis of variance (ANOVA) was used for statistical
analysis of the results in Figure 2,3,4,5,6 and Figure S3.
Bonferroni-holm test was conducted for post-hoc analysis if
statistically significant difference was found in comparison to the
most pathogenic or distinct strain in each subtype. Student’s t-test
was conducted for Figure 1, 7 and Figure S2. A p value of #0.05
was considered as significant.
Supporting Information
Figure S1 Clinical characteristics of uninfected ferrets.
Clinical signs of uninfected ferrets (N=6) were measured daily
over 14 days in the same approach as the infected groups.
Temperature A) and weight B) were recorded daily and are
expressed as percentage relative to the baseline level at Day 0.
Nasal discharge, sneezing and activity level C) were observed daily
and the highest percentages and fractions of ferrets displaying
symptoms are shown. Physical inactivity index measures the
degree to which ferrets respond to environmental stimuli with a
basal level of 1.000. Error bars represent standard error of the
mean.
(TIF)
Figure S2 Clinical characteristics of H1N1pdm infected
ferrets at 10
6EID50. Clinical signs of ferrets infected with A/
Mexico/4108/2009 (N=8 between Day 0 to Day 6 pI, N=5
between Day 7 to Day 14) and A/California/07/2009 (N=8
between Day 0 to Day 6 pI, N=6 between Day 7 to Day 9 and
N=5 between Day 10 to Day 14) were measured over a 14-day
time course. Body temperature A) and weight B) were recorded
daily until Day 14 pI. Both measurements are expressed as
percentage relative to the pre-infection level at Day 0. C)
summarises percent nasal discharge, percent sneezing and
inactivity index. These signs were observed daily and the highest
percentages and fractions of infected ferrets displaying symptoms
are shown. Physical inactivity index measures the degree to which
ferrets respond to environmental stimuli with a basal level of
1.000. Error bars represent standard error of the mean. *p,0.05
from Student’s t-test.
(TIF)
Figure S3 Clinical characteristics of influenza subtype
infections in ferrets at 10
6EID50. Ferret clinical data from
H1N1pdm (N=16 between Day 0 to Day 6 pI, N=11 between
Day 7 to Day 9 and N=10 between Day 10 to Day 14), seasonal
A/H1N1 (N=22), seasonal A/H3N2 (N=34 and N=31 after
Day 8 pI), and seasonal influenza B (N=20) infections were
combined respectively for inter-group comparison. The combined
body temperature A) and body weight B) are expressed as
percentage relative to the pre-infection level at Day 0. Percent
nasal discharge, percent sneezing, and physical inactivity index are
recalculated for each group and summarized in C). Amount of
animals displaying nasal discharge and sneezing from each group
were combined and calculated as percentage for each day. Only
the highest percentages and fractions from each group are shown.
Physical inactivity index is the pooled measure of which infected
ferrets by each group respond to environmental stimuli with a
basal level of 1.000. Error bars stand for standard error of the
Distinct Clinical Features of Influenza Infections
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Bonferroni-holm test (post-hoc analysis).
(TIF)
Acknowledgments
Influenza viruses (B/Brisbane/60/2008, B/Florida/04/2006, A/South
Carolina/2/2010, A/Mexico/4108/2009, A/Utah/20/2009, A/Bris-
bane/10/2007, A/Perth/16/2009, A/Wisconsin/15/2009, A/Victoria/
210/2009, B/Hubei-Wujiagang/158/2009, and B/Wisconsin/01/2010)
were obtained through the Influenza Reagent Resource, Influenza
Division, WHO Collaborating Center for Surveillance, Epidemiology
and Control of Influenza, Centers for Disease Control and Prevention,
Atlanta, GA, USA.
Author Contributions
Conceived and designed the experiments: SSHH DB AAK DJK.
Performed the experiments: SSHH DB YF DCKN TK. Analyzed the
data: SSHH DB AAK DJK. Contributed reagents/materials/analysis
tools: DJK. Wrote the paper: SSHH.
References
1. Munster VJ, Fouchier RA (2009) Avian influenza virus: of virus and bird
ecology. Vaccine 27: 6340–6344.
2. Sym D, Patel PN, El Chaar GM (2009) Seasonal, avian, and novel H1N1
influenza: prevention and treatment modalities. Ann Pharmacother 43:
2001–2011.
3. Girard MP, Tam JS, Assossou OM, Kieny MP (2010) The 2009 A (H1N1)
influenza virus pandemic: A review. Vaccine 28: 4895–4902.
4. Khanna M, Kumar P, Choudhary K, Kumar B, Vijayan VK (2008) Emerging
influenza virus: a global threat. J Biosci 33: 475–482.
5. Rajagopal S, Treanor J (2007) Pandemic (avian) influenza. Semin Respir Crit
Care Med 28: 159–170.
6. Influenza (Seasonal). World Health Organization (WHO). Available: http://
www.who.int/mediacentre/factsheets/fs211/en/index.html. Accessed 2011 Oct
19.
7. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003)
Mortality associated with influenza and respiratory syncytial virus in the United
States. JAMA 289: 179–186.
8. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005)
Characterization of a novel influenza A virus hemagglutinin subtype (H16)
obtained from black-headed gulls. J Virol 79: 2814–2822.
9. Hay AJ, Gregory V, Douglas AR, Lin YP (2001) The evolution of human
influenza viruses. Philos Trans R Soc Lond B Biol Sci 356: 1861–1870.
10. Holmes EC (2009) RNA virus genomics: a world of possibilities. J Clin Invest
119: 2488–2495.
11. Capua I, Alexander DJ (2002) Avian influenza and human health. Acta Trop 83:
1–6.
12. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82–S87.
13. World Health Organization (WHO) (2009) Characteristics of the emergent
influenza A (H1N1) viruses andrecommendations for vaccine development.
Avaliable: http://www.who.int/csr/resources/publications/swineflu/
H1N1Vaccinevirusrecommendation26May2009.pdf. Accessed 2011 Oct 19.
14. Nobusawa E, Sato K (2006) Comparison of the mutation rates of human
influenza A and B viruses. J Virol 80: 3675–3678.
15. Yamashita M, Krystal M, Fitch WM, Palese P (1988) Influenza B virus
evolution: co-circulating lineages and comparison of evolutionary pattern with
those of influenza A and C viruses. Virology 163: 112–122.
16. Matsuzaki Y, Sugawara K, Takashita E, Muraki Y, Hongo S, et al. (2004)
Genetic diversity of influenza B virus: the frequent reassortment and
cocirculation of the genetically distinct reassortant viruses in a community.
J Med Virol 74: 132–140.
17. Lindstrom SE, Hiromoto Y, Nishimura H, Saito T, Nerome R, et al. (1999)
Comparative analysis of evolutionary mechanisms of the hemagglutinin and
three internal protein genes of influenza B virus: multiple cocirculating lineages
and frequent reassortment of the NP, M, and NS genes. J Virol 73: 4413–4426.
18. Tang JW, Tambyah PA, Lai FY, Lee HK, Lee CK, et al. (2010) Differing
symptom patterns in early pandemic vs seasonal influenza infections. Arch
Intern Med 170: 861–867.
19. Kaji M, Watanabe A, Aizawa H (2003) Differences in clinical features between
influenza A H1N1, A H3N2, and B in adult patients. Respirology 8: 231–233.
20. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. (2009)
Hospitalized patients with 2009 H1N1 influenza in the United States, April-June
2009. N Engl J Med 361: 1935–1944.
21. Patel M, Dennis A, Flutter C, Khan Z (2010) Pandemic (H1N1) 2009 influenza.
Br J Anaesth 104: 128–142.
22. World Health Organization (WHO) (2002) WHO Manual on Animal
InfluenzaDiagnosis and Surveillance. Available: http://www.who.int/
vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_
surveillance_2002_5.pdf. Accessed 2011 Oct 19.
23. Influenza FluNet. World Health Organization (WHO). Available: http://www.
who.int/influenza/gisrs_laboratory/flunet/en/. Accessed 2011 Oct 19.
24. Hamelin ME, Baz M, Abed Y, Couture C, Joubert P, et al. (2010) Oseltamivir-
resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in
mice and ferrets. PLoS Pathog 6: e1001015.
25. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in
vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460:
1021–1025.
26. Jakeman KJ, Tisdale M, Russell S, Leone A, Sweet C (1994) Efficacy of 29-
deoxy-29-fluororibosides against influenza A and B viruses in ferrets. Antimicrob
Agents Chemother 38: 1864–1867.
27. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, et al. (2009)
Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses
in ferrets and mice. Science 325: 484–487.
28. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009)
Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in
ferrets. Science 325: 481–483.
29. Rowe T, Leon AJ, Crevar CJ, Carter DM, Xu L, et al. (2010) Modeling host
responses in ferrets during A/California/07/2009 influenza infection. Virology
401: 257–265.
30. Zhou B, Li Y, Belser JA, Pearce MB, Schmolke M, et al. (2010) NS-based live
attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 28:
8015–8025.
31. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, et al. (2002) Pathogenesis of
avian influenza A (H5N1) viruses in ferrets. J Virol 76: 4420–4429.
32. Recommendations for Influenza Vaccine Composition. World Health Organi-
zation (WHO). Available: http://www.who.int/influenza/vaccines/virus/
recommendations/en/index.html. Accessed 2011 Oct 19.
33. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, et al.
(2009) Pandemic potential of a strain of influenza A (H1N1): early findings.
Science 324: 1557–1561.
34. Guarner J, Falcon-Escobedo R (2009) Comparison of the pathology caused by
H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 40: 655–661.
35. O’Riordan S, Barton M, Yau Y, Read SE, Allen U, et al. (2010) Risk factors and
outcomes among children admitted to hospital with pandemic H1N1 influenza.
CMAJ 182: 39–44.
36. World Health Organization (WHO) (2010) Recommended viruses for influenza
vaccines for use in the 2010–2011 northern hemisphere influenza season.
Available: http://www.who.int/influenza/vaccines/virus/recommendations/
201002_Recommendation.pdf. Accessed 2011 Oct 19.
37. World Health Organization (WHO) (2009) Recommended composition of
influenza virus vaccines for use in the 2010 southern hemisphere influenza season.
Available: http://www.who.int/influenza/vaccines/200909_Recommendation.
pdf. Accessed 2011 Oct 19.
38. Rowe T, Banner D, Farooqui A, Ng DC, Kelvin AA, et al. (2010) In vivo
ribavirin activity against severe pandemic H1N1 influenza A/Mexico/4108/
2009. J Gen Virol 91: 2898–2906.
39. Reuman PD, Keely S, Schiff GM (1989) Assessment of signs of influenza illness
in the ferret model. J Virol Methods 24: 27–34.
40. Fang Y, Rowe T, Leon AJ, Banner D, Danesh A, et al. (2010) Molecular
characterization of in vivo adjuvant activity in ferrets vaccinated against
influenza virus. J Virol 84: 8369–8388.
Distinct Clinical Features of Influenza Infections
PLoS ONE | www.plosone.org 14 November 2011 | Volume 6 | Issue 11 | e27512